These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 26072680)

  • 1. Comparative Analysis of Pharmacophore Features and Quantitative Structure-Activity Relationships for CD38 Covalent and Non-covalent Inhibitors.
    Zhang S; Xue X; Zhang L; Zhang L; Liu Z
    Chem Biol Drug Des; 2015 Dec; 86(6):1411-24. PubMed ID: 26072680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insight into the Structural Determinants of Imidazole Scaffold-Based Derivatives as TNF-α Release Inhibitors by in Silico Explorations.
    Wang Y; Wu M; Ai C; Wang Y
    Int J Mol Sci; 2015 Aug; 16(9):20118-38. PubMed ID: 26307982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Docking-based CoMFA and CoMSIA studies on naphthyl-substituted diarylpyrimidines as NNRTIs.
    Wu HQ; Yao J; He QQ; Chen FE
    SAR QSAR Environ Res; 2014; 25(10):761-75. PubMed ID: 25242254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacophore modeling, virtual screening and 3D-QSAR studies of 5-tetrahydroquinolinylidine aminoguanidine derivatives as sodium hydrogen exchanger inhibitors.
    Bhatt HG; Patel PK
    Bioorg Med Chem Lett; 2012 Jun; 22(11):3758-65. PubMed ID: 22546667
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Liu J; Feng K; Ren Y
    J Biomol Struct Dyn; 2019 Sep; 37(14):3803-3821. PubMed ID: 30261821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular docking and CoMFA studies of thiazoloquin(az)olin(on)es as CD38 inhibitors: determination of inhibitory mechanism, pharmacophore interactions, and design of new inhibitors.
    Sepehri B; Ghavami R
    J Biomol Struct Dyn; 2017 Jul; 35(9):1890-1898. PubMed ID: 27577102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative Molecular Field Analysis (CoMFA) and Comparative Molecular Similarity Indices Analysis (CoMSIA) studies on α(1A)-adrenergic receptor antagonists based on pharmacophore molecular alignment.
    Zhao X; Chen M; Huang B; Ji H; Yuan M
    Int J Mol Sci; 2011; 12(10):7022-37. PubMed ID: 22072933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Computational Analysis of CRTh2 receptor antagonist: A Ligand-based CoMFA and CoMSIA approach.
    Babu S; Sohn H; Madhavan T
    Comput Biol Chem; 2015 Jun; 56():109-21. PubMed ID: 25935115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design of novel FLT-3 inhibitors based on dual-layer 3D-QSAR model and fragment-based compounds in silico.
    Shih KC; Lin CY; Chi HC; Hwang CS; Chen TS; Tang CY; Hsiao NW
    J Chem Inf Model; 2012 Jan; 52(1):146-55. PubMed ID: 22142286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design of new CD38 inhibitors based on CoMFA modelling and molecular docking analysis of 4‑amino-8-quinoline carboxamides and 2,4-diamino-8-quinazoline carboxamides.
    Sepehri B; Ghavami R
    SAR QSAR Environ Res; 2019 Jan; 30(1):21-38. PubMed ID: 30489181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A systematic quantitative approach to rational drug design and discovery of novel human carbonic anhydrase IX inhibitors.
    Sethi KK; Verma SM
    J Enzyme Inhib Med Chem; 2014 Aug; 29(4):571-81. PubMed ID: 24090419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemometric design to explore pharmacophore features of BACE inhibitors for controlling Alzheimer's disease.
    Hossain T; Mukherjee A; Saha A
    Mol Biosyst; 2015 Feb; 11(2):549-57. PubMed ID: 25435329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 3D-QSAR studies of Checkpoint Kinase Weel inhibitors based on molecular docking, CoMFA and CoMSIA.
    Yi P; Fang X; Qiu M
    Eur J Med Chem; 2008 May; 43(5):925-38. PubMed ID: 17698256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacophore modeling, 3D-QSAR, and docking study of pyrozolo[1,5-a]pyridine/4,4-dimethylpyrazolone analogues as PDE4 selective inhibitors.
    Tripuraneni NS; Azam MA
    J Mol Model; 2015 Nov; 21(11):289. PubMed ID: 26499496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-based and multiple potential three-dimensional quantitative structure-activity relationship (SB-MP-3D-QSAR) for inhibitor design.
    Du QS; Gao J; Wei YT; Du LQ; Wang SQ; Huang RB
    J Chem Inf Model; 2012 Apr; 52(4):996-1004. PubMed ID: 22480344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploring QSAR and pharmacophore mapping of structurally diverse selective matrix metalloproteinase-2 inhibitors.
    Halder AK; Saha A; Jha T
    J Pharm Pharmacol; 2013 Oct; 65(10):1541-54. PubMed ID: 24028622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design of novel quinazolinone derivatives as inhibitors for 5HT7 receptor.
    Chitta A; Jatavath MB; Fatima S; Manga V
    J Recept Signal Transduct Res; 2012 Feb; 32(1):3-16. PubMed ID: 22171569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stepwise development of structure-activity relationship of diverse PARP-1 inhibitors through comparative and validated in silico modeling techniques and molecular dynamics simulation.
    Halder AK; Saha A; Saha KD; Jha T
    J Biomol Struct Dyn; 2015; 33(8):1756-79. PubMed ID: 25350685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Three-dimensional quantitative structure: activity relationship studies on diverse structural classes of HIV-1 integrase inhibitors using CoMFA and CoMSIA.
    Nunthaboot N; Tonmunphean S; Parasuk V; Wolschann P; Kokpol S
    Eur J Med Chem; 2006 Dec; 41(12):1359-72. PubMed ID: 17002889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure based 3D-QSAR studies of Interleukin-2 inhibitors: Comparing the quality and predictivity of 3D-QSAR models obtained from different alignment methods and charge calculations.
    Halim SA; Zaheer-ul-Haq
    Chem Biol Interact; 2015 Aug; 238():9-24. PubMed ID: 26051521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.